{
  "abstract": "Introduction: This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan.\n\nMethods: Patients who initiated daprodustat between September 2020 and July 2022 were registered. The observation period was 52 weeks from treatment start or until discontinuation to assess overall safety, with an additional 52‐week follow‐up for cancer‐related events.\n\nResults: Of 1634 patients in the safety analysis set, adverse drug reactions (ADRs) occurred in 5.6% (4.8% not undergoing dialysis; 6.9% undergoing peritoneal dialysis; 6.6% undergoing hemodialysis) and serious ADRs in 2.2%. ADRs related to thromboembolism, hypertension, cardiovascular events, cancer, and retinal hemorrhage were reported in less than 1%, with no progression of autosomal dominant polycystic kidney disease. During follow‐up, no increase in cancer‐related events was observed.\n\nConclusions: No new safety concerns were identified for daprodustat in the real‐world setting in Japan.\n\nTrial Registration: GSK study: 214119",
  "abstract_shown": true,
  "affiliations": [
    "Division of Nephrology, Department of Medicine Showa Medical University Tokyo Japan",
    "Real‐World Data Analytics, Biostatistics, Asia Development GlaxoSmithKline K.K Tokyo Japan",
    "Safety Risk Evaluation, Clinical Safety & Pharmacovigilance GlaxoSmithKline K.K Tokyo Japan",
    "Specialty Medical Affairs, Specialty Medical Affairs and Development, Japan Medical Affairs GlaxoSmithKline K.K Tokyo Japan",
    "Safety Evaluation & Risk Management, Clinical Safety & Pharmacovigilance GlaxoSmithKline K.K Tokyo Japan",
    "Real‐World Evidence & Health Outcome Research, Japan Medical Affairs GlaxoSmithKline K.K Tokyo Japan"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tadao Akizawa",
      "orcid": "0000-0002-6150-9201"
    },
    {
      "affs": [
        1
      ],
      "name": "Kyomi Kanaya"
    },
    {
      "affs": [
        1
      ],
      "name": "Kiyomi Aizawa"
    },
    {
      "affs": [
        2
      ],
      "name": "Masanori Onoki"
    },
    {
      "affs": [
        3
      ],
      "name": "Hirofumi Ozeki"
    },
    {
      "affs": [
        4
      ],
      "name": "Kazuko Suzuki"
    },
    {
      "affs": [
        5
      ],
      "name": "Ai Hayashi"
    },
    {
      "affs": [
        5
      ],
      "name": "Tomohiko Asamura",
      "orcid": "0009-0001-9079-8030"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/05wq4kywva6bp.bib",
  "cited_by": 0,
  "doi": "10.1002/1744-9987.70182",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13738054/",
  "id": "05wq4kywva6bp",
  "issns": [
    "1744-9979",
    "1744-9987"
  ],
  "landing_url": "https://doi.org/10.1002/1744-9987.70182",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2720|Erythropoietin and Anemia Treatment"
    ]
  ],
  "openalex": "W7167499828",
  "pdf_url": null,
  "pmcid": "PMC13738054",
  "pmid": "42409622",
  "published": "2026-07-06",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/05wq4kywva6bp.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T12:23:07Z",
      "native_id": "PMC13738054",
      "source": "pmc",
      "url": "https://doi.org/10.1002/1744-9987.70182"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2720|Erythropoietin and Anemia Treatment",
      "subfield": "general"
    }
  ],
  "title": "Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan",
  "title_text": "Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:23:07Z",
  "url": "https://research.draconitic.com/paper/05wq4kywva6bp",
  "venue": "Therapeutic Apheresis and Dialysis",
  "versions": []
}